- Home
- ABTS vs TCRT Comparison
ABTS vs TCRT Comparison
Compare ABTS & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | TCRT |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 4.2M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ABTS | TCRT |
|---|---|---|
| Price | $1.42 | $1.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 60.9K | 11.3K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $1.55 |
| 52 Week High | $10.86 | $4.57 |
Technical Indicators
Market Signals| Indicator | ABTS | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 53.92 | 29.03 |
| Support Level | $1.02 | $1.55 |
| Resistance Level | $1.54 | $2.03 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 56.99 | 12.38 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a bitcoin mining company. The Company operates self-owned and hosted bitcoin mining facilities in Tennessee, United States.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.